POET Technologies Inc., together with its subsidiaries, designs, develops, manufactures, and sells semiconductor products and services for commercial applications in the United States, Canada, the rest of North and South…
FAIL · Does not pass the screen
4.26 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price4.26 USD at the 5 Nov 2026 close
Fair valueUnder review: only one analyst covers it, too few to cross-check it; our model's value is 2.90x the price, above our 1.35x limit.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.42, read 2026-11-01
Ethical does not pass the values gate
Price4.26 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markdown7.79-45.3% to today ✓Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation7.80-45.4% to today Markdown gives way to Accumulation
2026-09-09Read Markdown8.19-48.0% to today ✓Distribution gives way to Markdown after an 11% rise in 4 weeks
2026-08-09Read Distribution7.39-42.4% to today ✓Markup gives way to Distribution after a 41% slide in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
POET Technologies Inc. holds its Markdown at $4.26. The statistical read favours the sellers, held for 42 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 42 days
Price at the screen
$4.26
Valuation
N/A trailing · -33.35 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.84
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.15%
Below 33%
Interest-bearing debt is just 2.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
83.22%
Below 33%
Interest-bearing cash and securities are 83.2% of assets, above the one-third limit.
Fail
Receivables
12.16%
Below 49%
Money owed to the company is 12.2% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
POET Technologies's business is fine, but its cash and interest-bearing securities are about 83% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when POET's ethical verdict changes
Today POET does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Only one analyst covers it, too few to cross-check it; our model's value is 2.90x the price, above our 1.35x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Semiconductor Startup Chasing Revenue But No Profits
Picture a small Canadian outfit building optical chips that promise to speed up data centres and AI hardware. POET shows 202% revenue growth and clears our ethical screen, yet it remains unprofitable with zero profit margins and a negative 34% return on equity. The forward price to earnings sits at minus 43.5 times, and with only one analyst covering it the market offers no clear consensus.
We pass on this name because the business sits in a classic cyclical sector where rapid sales spikes often coincide with peak demand rather than durable earnings power. A 35% gap to our internal fair value looks attractive on paper, yet history shows such multiples compress quickly once orders normalise and capital needs rise. Unknown competitive moat adds further uncertainty.
Valuation multiples in cyclical chip names frequently mask the risk of earnings collapse rather than signal a bargain. Currency swings, customer concentration and execution delays on new designs sit among the real threats here. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Canada and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
POET trades on Nasdaq (the company is based in Canada). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markdown$5.20-8.3%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-10-25Markdown$5.67-2.9%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 23% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-10-18Markdown$5.84-25.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 25.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 90% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-10-11Markdown · changed$7.79-0.1%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 90% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-10-02Accumulation · changed$7.80-4.8%Entry 6
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 90% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-09-09Markdown · changed$8.19+10.8%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 10.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 90% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 41.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 90% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-07-18Markup$12.53+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 90% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (2 analysts) rates it none, with a mean price target of $8.
2026-07-03Markup$12.53+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$12.53Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
